Biobehavioral Measurement Core

生物行为测量核心

基本信息

批准号：
10181008
负责人：
ANNA L MARSLAND
金额：
$ 45.61万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-04-01 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10181008
关键词：
Address Adherence Adult Alcohol consumption Archives Atherosclerosis Baroreflex Behavior Behavioral Behavioral Medicine Biological Biological Monitoring Blood Pressure Brain C-reactive protein Cardiovascular Diseases Cardiovascular system Clinical Collection Consultations Data Data Collection Diet Dimensions Disease Doctor of Philosophy Dyslipidemias Ecological momentary assessment Education Endothelium Enrollment Ensure Epidemiology Evaluation Event Exercise F2-Isoprostanes Glucocorticoids Goals Health Health Benefit Health behavior Hydrocortisone Hypertension Image Immunology Individual Institutes Insulin Resistance Intercellular adhesion molecule 1 Interleukin-1 beta Interleukin-6 Intervention Studies Investigation Label Laboratories Laboratory Research Measurement Measures Mediator of activation protein Medical Monitor Neurobiology Non-Insulin-Dependent Diabetes Mellitus Obesity Outcome Outcome Measure Oxidative Stress Participant Pathway interactions Patient Self-Report Pharmaceutical Preparations Phase Physical activity Physician Executives Physicians Physiologic pulse Plasma Process Protocols documentation Psychology Public Domains Public Health Public Health Schools Recording of previous events Reporting Research Resistance Sampling Sentinel Serum Serum amyloid A protein Sleep Specimen Statistical Models Structure Study Subject TNF gene Testing Tobacco use Training and Education Ultrasonography Vascular Cell Adhesion Molecule-1 Vascular Diseases Vasodilation actigraphy arterial stiffness base biobehavior biobehavioral measurement biological specimen archives brain health cardiometabolic risk cardiorespiratory fitness cardiovascular disorder risk cardiovascular health carotid intima-media thickness circulating biomarkers clinical Diagnosis cohort data exchange data management density diaries exercise intervention follow up assessment follow-up heart rate variability hypothalamic-pituitary-adrenal axis longitudinal analysis medical schools middle age novel participant safety pre-clinical primary outcome professor programs quality assurance reactive hyperemia recruit relating to nervous system risk mitigation secondary outcome substance use synergism systemic inflammatory response

项目摘要

ABSTRACT Biobehavioral Measurement Core (Anna Marsland, CL) The objective of this Program Project is to elucidate the neurobiology of midlife disparities in cardiovascular disease (CVD) risk. Primary outcomes lay in 2 broad domains: (1) preclinical vascular disease and dysfunction and (2) cardiometabolic risk. Secondary outcomes are incident CVD events, hypertension, and type 2 diabetes. All projects (P's) postulate common proximal mediators of CVD risk, including health behaviors (e.g., substance use, customary diet, physical activity, and sleep), as well as candidate biomediators of autonomic control, systemic inflammation, endothelial and HPA-axis function, and oxidative stress. To enable uniform data collection and synergy across Ps, the Core B team will collect, verify and monitor shared Program outcomes and mediators, transfer data to Core C, and continuously report subject-by-subject protocol adherence to Core A. Core B will also oversee the quality assurance of all biobehavioral measures, provide centralized storage of biological specimens relevant to longitudinal testing, offer consultation and education on biobehavioral measures to all P teams, and assist with interpreting findings. For longitudinal analyses, all measurements obtained at T1 that address the aims of P's 1-3 will be re-obtained at follow-up assessments, and new or expanded measurements will be obtained as is feasible and advantageous to capture sentinel predictors, mediators and outcomes impacting CVD risk. We will collect data on 899 people recruited to P's 1-3. Core B is led by Dr. Marsland, Director of the Behavioral Immunology Laboratory where biological samples will be processed and stored. She is assisted by a Core Medical Director and Ambulatory Division Leader. The Medical Director is a physician who will assume oversight of participant-reported clinical diagnoses and events, as well as participant safety monitoring and associated risk mitigation strategies. The Ambulatory Division Leader will provide oversight of all ambulatory measures commonly obtained in the Program cohorts, including ecological momentary assessment diary data, ambulatory blood pressure, and actigraphy data.

抽象的生物行为测量核心（Anna Marsland，CL）该计划项目的目的是阐明心血管中期差异的神经生物学疾病（CVD）风险。主要结果在两个广泛的领域：（1）临床前血管疾病和功能障碍（2）心脏代谢风险。次要结果是事件CVD事件，高血压和2型糖尿病。所有项目（P）假定CVD风险的常见近端介体，包括健康行为（例如，药物使用，习惯饮食，体育锻炼和睡眠）以及自主神经的候选生物对象控制，全身炎症，内皮和HPA轴功能以及氧化应激。启用统一数据收集和协同跨PS，核心B团队将收集，验证和监视共享程序结果和调解人，将数据传输到核心C，并不断报告主题协议遵守核心A。核心B还将监督所有生物行为措施的质量保证，提供集中存储与纵向测试有关的生物标本，提供有关咨询和教育生物行为对所有P团队都措施，并协助解释发现。对于纵向分析，所有在T1获得的测量值，该测量应在后续评估中重新验证P 将获得新的或扩展的测量值，以捕获前哨预测变量，可行和有利影响CVD风险的调解人和结果。我们将收集有关招募到P的1-3人的899人的数据。核心是由Marsland博士领导的行为免疫学实验室主任，生物样品将是处理和存储。她得到了核心医疗总监和门诊部门负责人的协助。医疗董事是一名医生作为参与者安全监控和相关风险缓解策略。门诊师的负责人将提供对计划队列中通常获得的所有门诊措施的监督，包括生态瞬时评估日记数据，卧床血压和行为数据。